Receipt of pazopanib did not improve health-related quality of life (HRQoL) in patients with advanced soft tissue sarcoma, a recent study published online ahead of print in the journal Cancer has shown.
The global, double-blind, phase III PALETTE trial evaluated the efficacy of pazopanib 800 mg compared with placebo as second-line or later treatment in 369 patients with advanced soft tissue sarcoma.
The study found that median progression-free survival was 4.6 months in the pazopanib arm versus 1.6 months in the placebo arm (HR = 0.31; P<0.001).
Continue Reading
In this exploratory analysis, researchers sought to assess the impact of pazopanib on HRQoL, which was evaluated using the 30-item core EORTC QoL Questionnaire.
Results showed that differences in scores on the EORTC QoL Questionnaire global health status subscale were not statistically significant between the two treatment arms. Researchers found that patients who received pazopanib reported significantly worse outcome scores for diarrhea (P<0.001), nausea/vomiting (P<0.001), loss of appetite (P<0.001), and fatigue (P=0.012). In both arms, HRQoL tended to decline over time.
RELATED: Addition of IFN-a-2b to MAP Does Not Improve Event-Free Survival in Osteosarcoma
The findings suggest that although pazopanib did not improve HRQoL, it did not result in a reduction of worse overall global health status while simultaneously improving progression-free survival, which the researchers consider to be a meaningful result.
Reference
